Analytical Data
-
Gene name
VAX1
- Application
-
Alternative Names
VAX1; Ventral anterior homeobox 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5SQQ9
-
Expression Region
1-334 aa
-
AA Sequence
MFGKPDKMDV RCHSDAEAAR VSKNAHKESR ESKGAEGNLP AAFLKEPQGA FSASGAAEDC NKSKSNSAAD PDYCRRILVR DAKGSIREII LPKGLDLDRP KRTRTSFTAE QLYRLEMEFQ RCQYVVGRER TELARQLNLS ETQVKVWFQN RRTKQKKDQG KDSELRSVVS ETAATCSVLR LLEQGRLLSP PGLPALLPPC ATGALGSALR GPSLPALGAG AAAGSAAAAA AAAPGPAGAA SPHPPAVGGA PGPGPAGPGG LHAGAPAAGH SLFSLPVPSL LGSVASRLSS APLTMAGSLA GNLQELSARY LSSSAFEPYS RTNNKEGAEK KALD
-
Molecular Weight
34.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
VAX1, or Ventral Anterior Homeobox 1, is a homeobox gene that plays a critical role in embryonic development, particularly in the formation of the central nervous system and the specification of embryonic patterning. Research has shown that VAX1 is essential for the proper development of various organ systems, including the eyes and the forebrain. Its expression is tightly regulated, and any alterations can lead to developmental disorders and congenital anomalies. The study of VAX1 recombinant proteins has gained attention for their potential applications in both basic research and therapeutic interventions. By producing VAX1 in a recombinant form, scientists can investigate its biological functions, signaling pathways, and interactions with other proteins more effectively. This can lead to a better understanding of its role in developmental processes and disease mechanisms. Additionally, exploring the potential for VAX1 as a biomarker or therapeutic target in various conditions, such as retinal diseases and neurological disorders, signifies its importance in translational research. The insights gained from VAX1 recombinant protein studies may also contribute to novel gene therapy strategies or regenerative medicine products aimed at correcting developmental defects associated with VAX1 dysfunction. Overall, the investigation of VAX1 and its recombinant protein forms represents a promising avenue for advancing our understanding of developmental biology and improving clinical outcomes in related health issues.
